Aims Regular physical activity plays a major role, in both prevention and treatment of type 2 diabetes. Less is known whether vigorous physical activity during young adulthood is associated with costs of diabetes medication in later life. The aim of this study is to evaluate this question. Methods The study population consisted of 1314 former elite-class athletes and 860 matched controls. The former athletes were divided into three groups based on their active career sport: endurance, mixed and power sports. Conclusions A career as former endurance, sprint, jumper or team game athlete seems to reduce the costs of diabetes medication in later life.
Introduction
The burden of diabetes is increasing worldwide [1] . Regular physical activity is one of the corner stones in both prevention and treatment of type 2 diabetes [2] [3] [4] [5] [6] [7] . Based on previous studies, vigorous physical activity during young adulthood as well as an active lifestyle seems to be associated with a lower prevalence of type 2 diabetes in later life [8, 9] . Also, it has been shown that structured exercise training consisting of aerobic exercise, resistance training or both combined is associated with better glycemic control in patients with type 2 diabetes [10] [11] [12] . However, only little long-term data exist on the optimal timing, intensity and frequency of exercise training in relation to glucose control in patients with type 2 diabetes [13, 14] . Physical activity has several other favourable effects on an individual's life, for example improved functional status and ameliorated physical fitness [15] . However, less is known whether vigorous physical activity during young adulthood has any effect on the costs of diabetes medication in later life. A questionnaire-based study including Finnish male former elite athletes and their matched controls was initiated in 1985 [16] . Male former elite athletes have a documented history of vigorous physical activity in their past, generally spanning from adolescence to late 20 or 30 s. This enables research focusing upon the long-term effects of physical activity on different health-related aspects without the need to actually measure physical activity in young adulthood.
The aim of this study is to evaluate whether a career as an elite-class athlete has any effect on the costs of diabetes medication in later life.
Subjects and methods

Subjects
The original study cohort (N = 4136) consists of male former elite athletes (n = 2424) who represented Finland between the years 1920 and 1965 at least once in international competitions (Olympic games, World or European championships or other inter-country competitions) and their matched controls (n = 1712) [16] . The controls were classified as healthy at the medical examination, which all Finnish men undergo at age of 20 years as part of the national military service. Male former elite athletes were divided into three groups according to the type of training needed to achieve optimal results [17] : endurance sports (long-and middle-distance running, cross-country skiing), mixed sports (soccer, ice hockey, basketball, track and field: jumpers, sprinters, hurdles, decathletes) and power sports (boxing, wrestling, weight lifting, track and field throwers).
Those who were alive in the year 1995 when medication data collection was initiated are included in this study; 1314 former elite athletes and 860 controls, in total 2174 individuals (for flow chart, see Fig. 1 ). One power sport athlete had type 1 diabetes.
Methods
The outcome of this study comprised of register-based purchases of diabetes medication (Anatomical Therapeutic In this study, data on diabetes medications including the costs of medications were divided into two classes: insulin (ATC-code A10A) and other diabetes drugs (ATC-codes A10B and A10X) [18] .
The cumulative incidence of diabetes was calculated based upon diabetes drug purchases according to the Finnish Social Insurance Institution prescription register and the participants' self-report on diabetes (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) ).
The yearly sums of the costs of each medication group (ATC-codes A10A and ATC-codes A10B and/or A10X) were computed for each user and adjusted to correspond to the nominal EURO values in the year 2010. The inflation correction was computed based on the annual averages of the Finnish consumer price index provided by Official Statistics of Finland [19] .
In the year 1985, a questionnaire was sent to all living former athletes and their controls [16] . From the questionnaires, we obtained data on self-reported diabetes and occupation. The occupation of each participant was classified according to the one where he has been in most of his lifetime. Based on the Finnish classification of occupations, the participants were grouped into four groups: highly educated (management and professionals), white-collar workers (experts, office workers and clerks), blue-collar workers (service, sales, construction, repair, manufacturing, process and transport workers), and farmers, others or unskilled [20] . There were missing data for 94 participants. Date of death was obtained from the Cause-of-Death Bureau at Statistics Finland.
Statistical analysis
Data are reported as mean (standard deviations, SD) or number (percentage, %). Statistical comparisons were made by using analysis of variance (ANOVA) and post hoc testing with Dunnett, or analysis of covariance (ANCOVA) and post hoc testing of several univariate comparisons were made with Hochberg's, adjustment at significance level 0.05. As the data for costs were highly skewed, bias-corrected and accelerated bootstrap estimation was used for statistical comparison and derived 95% confidence intervals. Time-to-event analysis is based on the product limit estimate of the cumulative 'survival' function. Stata 14.1, StataCorp LP (College Station, TX, USA) statistical package was used for the analyses.
Results
Response rate and basic characteristics
The response rate to the questionnaires sent in 1985 was 77.1% in the whole study population, 82.0% in the endurance group, 79.7% in the mixed sport group, 78.1% in the power sport group and 73.4% in the control group, respectively. In 1985, among endurance athletes, one participant had selfreported diabetes, and the corresponding numbers were six among the mixed sport group athletes, 12 among power sport athletes and 25 among controls, respectively.
The former endurance athletes were the oldest (Table 1) ; their mean (SD) birth year was 1926 (9.5), and that of the controls was 1932 (8.9) (p \ 0.001). Most of athletes from the endurance group were white-collar workers, in the mixed group highly educated, and in power and control group bluecollar workers, respectively ( Table 1) . The cumulative incidence of diabetes between 1995 and 2009 was lowest in the endurance group (Fig. 2) .
Costs of diabetes medication
Among all study subjects, the total cost of diabetes medication during the 15-year follow-up was significantly lower among the former athletes from the endurance group (mean 81 € [95% CI 33-151 €]), compared with the control group (mean 376 € [95% CI 284-485 €]), birth year adjusted p \ 0.001 (Table 2) . Of the former endurance athletes, 0.4% used insulin, 3.5% of the mixed sport athletes, 6.3% of the power athletes and 5.2% in the controls, respectively, between endurance and control group birth year adjusted p = 0.018. Among those study participants who had diabetes, the cost of insulin medication was significantly lower among the former athletes from the endurance group (mean 75 € [95% CI 0-277 €]), compared with the control group (mean 917 € [95% CI 600-1309 €]), birth year adjusted p B 0.001 (Table 2) .
Among all study subjects, the former athletes from the endurance and mixed group had significantly lower total cost of diabetes medication per person years than the controls, differences between endurance and control group p \ 0.001, and between mixed and control group p = 0.045, respectively (Fig. 3) . However, among the study subjects with diabetes, no significant differences were observed for total cost of diabetes medication per person years between the groups (p = 0.081) (Fig. 3) .
Discussion
The findings in this study show that a career as endurance, sprint, jumper or team game athlete mitigates the burden of cost of diabetes medication in later life. In particular, this is seen among the endurance athletes. Further, the use of insulin was extremely low among the former endurance athletes. However, restricting the analyses to subjects with diabetes attenuated the findings.
As far as we know, this is the first study evaluating the association between vigorous physical activity during young adulthood and the costs of diabetes medication in [21] . Furthermore, leisure-time physical activity levels among former elite-class endurance, sprint, jumper or team game athletes are typically higher than among the general population throughout the entire life course; however, this difference is not noticed between former eliteclass power athletes and the general population [15, 22] . Also differences in genetic factors between power sports athletes and other groups may explain the observed difference. Several lifestyle interventions studies aiming at prevention of type 2 diabetes have been focusing on middle-aged or older people, but the follow-up time of many of these intervention has been rather short [23] . Generally, lifestyle intervention consists of both diet and exercise counselling. Based on these studies, cost analysis has been made, including direct medical cost analysis, as well as modelling economic studies. According to these study findings, healthy lifestyle changes are cost-effective and the economic savings are bigger the earlier the counselling is initiated [24] [25] [26] [27] . Further, an Australian study showed in middle-aged people with pre-diabetes that exercise counselling was the third most cost-effective treatment after metformin therapy and diet and exercise counselling when aiming at prevention and slowing down the onset of diabetes [28] . Among overweight and obese persons with type 2 diabetes, those who had an intensive lifestyle intervention seem to have fewer hospitalizations, use less medication and have lower health-care costs than those with common diabetes support and education [7] . These observations are in line with our study findings. We found that endurance, sprint, jumper or team game athletes had a low cumulative incidence rate of type 2 diabetes. These results endorse previous study observations from the Male Former Elite Athletes Study, which have shown that a career as an elite-class athlete is associated with a low prevalence of diabetes [15, 22] .
What is behind the beneficial effects of regular physical activity?
Various mechanisms underlie the favourable effects of regular physical activity on glucose regulation and consequently also reflecting on the use of glucose lowering medication. Physical activity has an important role in glucose-insulin metabolism [29] [30] [31] [32] . During exercise training, there is an increase in skeletal muscle blood flow, recruitment of capillaries as well as in the expression and translocation of GLUT4-transporters [33, 34] . Increased GLUT4 expression is thought to enhance insulin sensitivity, glucose disposal and muscle glycogen storage [34, 35] . Further, people who do regular endurance-type training seem to have a higher proportion of type 1 muscle fibres, which have been associated with better insulin sensitivity [36, 37] . Physical exercise also seems to be associated with better mitochondrial function, thus improving muscle insulin sensitivity [38] . Physical activity seems to reduce body mass index and waist circumference [39, 40] . However, the study findings in relation to physical exercise and fat content in the liver are not unequivocal, and both beneficial effect and no effect have been reported [41] [42] [43] . Another possible explanation is that regular physical activity during young adulthood works through an 'exercise memory effect'. Overall, physical activity seems to influence glucose metabolism via several pathways.
Strengths of the study
The study population is globally unique, and the cohort size of elite-class athletes is considerably large. The eliteclass athletes have a well-documented history of vigorous physical activity during young adulthood. Further, the register held by the Finnish Defence Force made it possible Subjects with DM Fig. 3 Total costs of diabetes medication per person years (pyrs) in different athletes and control groups among all study subjects and the subjects with diabetes. Among all study subjects, the former athletes from the endurance and mixed group had significantly lower total cost of diabetes medication pyrs than the controls, differences between endurance and control group p B 0.001, and, respectively, between mixed and control group p = 0.045. However, among the study subjects with diabetes, no significant differences were observed for total cost of diabetes medication for pyrs between the groups (p = 0.081). The whiskers represent 95% CI. DM diabetes, E endurance, M mixed, P power, C controls, pyrs per person years to select the matched controls among those Finnish men who were classified as healthy at the age of 20 years. Finally, the Finnish Social Insurance Institution upholds a comprehensive prescription register, which enables us to link the diabetes medications purchases including the costs with the study participants.
Limitations of the study
Information on study participants' glucose control was not available. If the glucose control is non-optimal, it may affect diabetes medication and consequently also the cost. Unfortunately, we were missing data on BMI and leisure-time physical activity from almost every fourth study participants.
Although we found an association between former endurance-type sports participation and reduced need of diabetes medication, our study design did not allow definite analysis on how much of this association is explained by higher middle age or later life physical activity, which are higher among the former athletes than among the controls. Detailed information on sedentary habits or sleeping pattern was not available. All our participants were of European ancestry and men. Finally, the former elite-class athletes form a genetically selected group. Underlying genetic pleiotropy may explain some of the associations between becoming an eliteclass athlete, metabolic/aerobic fitness and later occurrence of metabolic disorders [44] .
Conclusions
A career as endurance, sprint, jumper or team game athlete seems to reduce the costs of diabetes medication in later life. Among male former athletes, the use of insulin is rare.
